88 related articles for article (PubMed ID: 38753747)
41. Nanoparticle Diagnostics and Theranostics in the Clinic.
Pallares RM; Mottaghy FM; Schulz V; Kiessling F; Lammers T
J Nucl Med; 2022 Dec; 63(12):1802-1808. PubMed ID: 36302654
[TBL] [Abstract][Full Text] [Related]
42. All-in-One Nanomedicine: Multifunctional Single-Component Nanoparticles for Cancer Theranostics.
Cai Y; Chen X; Si J; Mou X; Dong X
Small; 2021 Dec; 17(52):e2103072. PubMed ID: 34561968
[TBL] [Abstract][Full Text] [Related]
43. 2D Nanomaterials for Cancer Theranostic Applications.
Cheng L; Wang X; Gong F; Liu T; Liu Z
Adv Mater; 2020 Apr; 32(13):e1902333. PubMed ID: 31353752
[TBL] [Abstract][Full Text] [Related]
44. The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.
Pruis IJ; van Dongen GAMS; Veldhuijzen van Zanten SEM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033160
[TBL] [Abstract][Full Text] [Related]
45. General Concepts in Theranostics.
Nunes RF; Zuppani RMF; Coutinho AM; Barbosa FG; Sapienza MT; Marin JFG; Buchpiguel CA
PET Clin; 2021 Jul; 16(3):313-326. PubMed ID: 34053576
[TBL] [Abstract][Full Text] [Related]
46. Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases.
Dyer MR; Jing Z; Duncan K; Godbe J; Shokeen M
Nucl Med Biol; 2024; 130-131():108879. PubMed ID: 38340369
[TBL] [Abstract][Full Text] [Related]
47. Current status and future perspective of radiopharmaceuticals in China.
Hu J; Li H; Sui Y; Du J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2514-2530. PubMed ID: 34767047
[TBL] [Abstract][Full Text] [Related]
48. Radiopharmaceuticals and their use in the current practice of nuclear medicine.
Fejka RM
Lippincotts Prim Care Pract; 1999; 3(6):531-45. PubMed ID: 10889704
[No Abstract] [Full Text] [Related]
49. Nanoparticles Functionalised with Re(I) Tricarbonyl Complexes for Cancer Theranostics.
Mkhatshwa M; Moremi JM; Makgopa K; Manicum AE
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207182
[TBL] [Abstract][Full Text] [Related]
50. Nanoparticles for SPECT and PET Imaging: Towards Personalized Medicine and Theranostics.
Polyak A; Ross TL
Curr Med Chem; 2018; 25(34):4328-4353. PubMed ID: 28875837
[TBL] [Abstract][Full Text] [Related]
51. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
52. Near-infrared photothermally activated nanomachines for cancer theragnosis.
He Z; Zhu JJ
Dalton Trans; 2019 Sep; 48(35):13120-13124. PubMed ID: 31348472
[TBL] [Abstract][Full Text] [Related]
53. The Future of Nuclear Medicine as an Independent Specialty.
Czernin J; Sonni I; Razmaria A; Calais J
J Nucl Med; 2019 Sep; 60(Suppl 2):3S-12S. PubMed ID: 31481589
[TBL] [Abstract][Full Text] [Related]
54. Current state and prospects of the phytosynthesized colloidal gold nanoparticles and their applications in cancer theranostics.
Ovais M; Raza A; Naz S; Islam NU; Khalil AT; Ali S; Khan MA; Shinwari ZK
Appl Microbiol Biotechnol; 2017 May; 101(9):3551-3565. PubMed ID: 28382454
[TBL] [Abstract][Full Text] [Related]
55. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
56. Copper-64: a real theranostic agent.
Gutfilen B; Souza SA; Valentini G
Drug Des Devel Ther; 2018; 12():3235-3245. PubMed ID: 30323557
[TBL] [Abstract][Full Text] [Related]
57. Veterinary nuclear medicine.
Krzemiński M; Lass P; Teodorczyk J; Krajka J
Nucl Med Rev Cent East Eur; 2004; 7(2):177-82. PubMed ID: 15968607
[No Abstract] [Full Text] [Related]
58. Nuclear imaging in cancer theranostics.
Del Vecchio S; Zannetti A; Fonti R; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):152-63. PubMed ID: 17420716
[TBL] [Abstract][Full Text] [Related]
59. Gold nanoparticles enlighten the future of cancer theranostics.
Guo J; Rahme K; He Y; Li LL; Holmes JD; O'Driscoll CM
Int J Nanomedicine; 2017; 12():6131-6152. PubMed ID: 28883725
[TBL] [Abstract][Full Text] [Related]
60. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics.
Boschi A; Martini P; Janevik-Ivanovska E; Duatti A
Drug Discov Today; 2018 Aug; 23(8):1489-1501. PubMed ID: 29635027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
